Petrylak, Daniel P <br/><br/>
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.  [electronic resource] 

 -  Investigational new drugs  Apr 2015 
 - 397-408 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-014-0199-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Dehydroepiandrosterone Sulfate--blood<br/>Disease Progression<br/>Disease-Free Survival<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Naphthalenes--administration & dosage<br/>Prednisone--administration & dosage<br/>Prostate-Specific Antigen<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Steroid 17-alpha-Hydroxylase--antagonists & inhibitors<br/>Taxoids--administration & dosage<br/>Testosterone--blood